Sunshine Biopharma, Inc. operates as a pharmaceutical and nutritional supplement company primarily dedicated to the research and development of innovative anticancer drugs. The company's pipeline includes Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin. This compound is currently in development to address a broad spectrum of cancers, such as leukemia, lymphoma, and tumors affecting the testicular, lung, brain, prostate, bladder, colon, ovarian, and liver.